109 citations,
November 2004 in “Lupus” The paper concludes that the 1982 criteria for diagnosing systemic lupus erythematosus need updating to improve accuracy and involve dermatologists in the process.
101 citations,
November 1992 in “Archives of Dermatology” Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.
97 citations,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
87 citations,
July 2012 in “Expert Review of Clinical Immunology” Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.
75 citations,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
71 citations,
May 2019 in “Rheumatology” Tph cells are linked to the severity of systemic lupus erythematosus.
70 citations,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
58 citations,
January 2007 in “Dermatology” Minoxidil use in children may cause heart issues.
57 citations,
September 2016 in “Arthritis Care & Research” A risk prediction model can help diagnose systemic lupus erythematosus earlier in primary care.
57 citations,
March 2011 in “The American Journal of Dermatopathology” Chemotherapy can cause permanent, non-reversible hair loss similar to pattern baldness.
52 citations,
September 2021 in “Kidney International” COVID-19 vaccination may trigger lupus in some people.
49 citations,
February 2009 in “Clinical Rheumatology” SLE is more common among Nigerians than previously thought, especially in women, requiring early treatment.
47 citations,
August 2016 in “American Journal Of Pathology” Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.
46 citations,
June 2018 in “American Journal of Clinical Dermatology” Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.
41 citations,
September 2018 in “Australasian journal of dermatology” No systemic treatment for alopecia areata has strong evidence of effectiveness.
40 citations,
July 2007 in “Dermatologic Therapy” Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.
39 citations,
May 2019 in “Journal of the American Academy of Dermatology” Hair loss in lupus patients indicates higher disease activity.
39 citations,
January 2012 in “Acta dermato-venereologica” Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.
34 citations,
June 2007 in “The Journal of Dermatology” Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.
33 citations,
August 2013 in “Lupus” SLE patients in eastern Saudi Arabia have a generally good prognosis despite multi-organ involvement.
33 citations,
January 2011 in “Elsevier eBooks” Systemic Lupus Erythematosus has varied symptoms and is hard to diagnose, affecting many body parts and requiring careful clinical judgment.
31 citations,
March 2018 in “Frontiers in Immunology” The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.
30 citations,
October 2013 in “Lupus” Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.
30 citations,
August 1998 in “International Journal of Dermatology” Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.
29 citations,
January 2019 in “Journal of the European Academy of Dermatology and Venereology” Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.
26 citations,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
25 citations,
May 2017 in “InTech eBooks” Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.
24 citations,
July 1987 in “Dermatologic Clinics” Systemic diseases can cause hair loss, which is often reversible with treatment.
23 citations,
July 2015 in “Encyclopedia of Life Sciences” Systemic lupus erythematosus is a chronic disease causing inflammation and various symptoms, mainly in young women, treated with anti-inflammatory and immunosuppressive drugs.
22 citations,
November 2018 in “Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry” Most patients with Systemic Lupus Erythematosus experience fatigue, skin issues, and joint pain.